PDCD1 and hematologic disorder: CT-011 (pidilizumab), a humanized anti–PD-1 antibody, has been evaluated in multiple hematologic malignancies, demonstrating potential clinical activity in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia 13.